Drug Applications Face Rejection As China FDA Starts 'Intensive Review'
This article was originally published in SRA
Executive Summary
In a rare move, the China Food and Drug Administration has rejected 11 new drug applications (NDAs) from eight companies that were in its review queue, signaling more action to come as the agency increases punishments for clinical data forgery and prepares another intensive review campaign, its third in a decade.
You may also be interested in...
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.
Chinese Language Podcast: BIOSECURE Act, US PD-1 Approval, ADC Updates
Guest speaker and lawyer Kevin Duan joins Brian Yang and Dexter Yan to discuss the planned US BIOSECURE Act, the US approval of BeiGene's anti-PD-1 drug and the latest antibody-drug conjugates in development at Chinese pharma firms.
China Biotechs, CDMOs Embrace Uncertain Future, New Options Amid WuXi Woes
The shockwave of WuXi's withdrawal from BIO is ripping through the Chinese contract services sector. While some remain hopeful, others are preparing Plan B.